$CBLL News

BTIG Maintains Buy on CeriBell, Raises Price Target to $30

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26

BTIG Reiterates Buy on CeriBell, Maintains $28 Price Target

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...

CeriBell, Inc. Q2 2026 Earnings Call Summary

CeriBell (CBLL) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

CeriBell Q2 Earnings Call Highlights

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

Ceribell Reports Second Quarter 2026 Financial Results

CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est

CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction

CeriBell Shares Gain After Medicare Approves Additional Payment for Delirium Monitoring System

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026